Genor Biopharma Holdings Limited

HKSE 6998.HK

Genor Biopharma Holdings Limited Return on Capital Employed (ROCE) for the year ending December 31, 2023: -50.63%

Genor Biopharma Holdings Limited Return on Capital Employed (ROCE) is -50.63% for the year ending December 31, 2023, a -28.70% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Genor Biopharma Holdings Limited Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -39.34%, a -16.15% change year over year.
Genor Biopharma Holdings Limited Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -33.87%, a 62.85% change year over year.
Genor Biopharma Holdings Limited Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -91.16%, a 34.86% change year over year.
Genor Biopharma Holdings Limited Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -139.93%, a -342.15% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

HKSE: 6998.HK

Genor Biopharma Holdings Limited

CEO	Dr. Feng Guo Ph.D.
IPO Date	Oct. 7, 2020
Location	China
Headquarters	Building 3
Employees	28
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines

Description

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.

Key trends

Past 5 years